Met Life Investment Management, LLC Graphite Bio, Inc. Transaction History

Met Life Investment Management, LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 11, 2022	SELL	$2.14 - $5.23 $43,112 - $105,363	-20,146 Closed	0 $0
Q1 2022 May 10, 2024	BUY	$5.1 - $13.06 $102,744 - $263,106	20,146 New	20,146 $102,000
Q1 2022 Jun 20, 2023	BUY	$5.1 - $13.06 $102,744 - $263,106	20,146 New	20,146 $102,000
Q1 2022 Mar 22, 2023	BUY	$5.1 - $13.06 $67,753 - $173,502	13,285 Added 193.63%	20,146 $102,000
Q1 2022 May 12, 2022	BUY	$5.1 - $13.06 $102,744 - $263,106	20,146 New	20,146 $103,000
Q4 2021 Feb 15, 2022	SELL	$8.41 - $16.71 $57,701 - $114,647	-6,861 Closed	0 $0
Q3 2021 May 17, 2024	BUY	$15.81 - $28.39 $108,472 - $194,783	6,861 New	6,861 $112,000
Q3 2021 Jun 21, 2023	BUY	$15.81 - $28.39 $108,472 - $194,783	6,861 New	6,861 $112,000
Q3 2021 Mar 22, 2023	BUY	$15.81 - $28.39 $108,472 - $194,783	6,861 New	6,861 $112,000
Q3 2021 Nov 15, 2021	BUY	$15.81 - $28.39 $108,472 - $194,783	6,861 New	6,861 $112,000

637K

Ticker GRPH
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 58,211,200
Description
Graphite Bio, Inc., a clinical-stage gene editing company, engages in developing therapies for serious and life-threatening diseases in the United States. It offers GPH101, a gene-edited autologous hematopoietic stem cell product candidate to directly correct the mutation that causes sickle cell disease and restore normal adult hemoglobin expres...

Get notified when there are updates to the investment portfolio of Met Life Investment Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Met Life Investment Management, LLC with notifications on news.